This trial is evaluating whether Bortezomib will improve 1 primary outcome in patients with Hematologic Neoplasms. Measurement will happen over the course of within 30 days post transplant.
This trial requires 15 total participants across 1 different treatment group
This trial involves a single treatment. Bortezomib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"While the disease burden of hematologic neoplasms is high, many patients are diagnosed with hematologic cancer at the end-of-life, resulting in increased mortality. Most patients are treated with hematologic-type cytotoxic agents, including tyrosine kinase inhibitors, allogeneic stem cell transplantation, and the immunomodulatory therapy interferon-alpha and lenalidomide. Many patients have nonhematologic-related causes of cancer at the time of diagnosis, resulting in substantial mortality but may not be treatable, such as cancer metastasis to bone marrow, liver, and lung." - Anonymous Online Contributor
"Hematological neoplasms are often cured with a number of standard chemotherapy regimens. For refractory or relapsed leukemia, new and intensifying chemotherapy regimens should be initiated if clinical benefit can be sustained." - Anonymous Online Contributor
"There was a significantly higher incidence of hematologic neoplasms in the United States in 2011 than in 1990 (P <.001). The mean annual incidence of lymphoma in the United States had significantly increased since 1990." - Anonymous Online Contributor
"Signs of hematologic neoplasms include low number of circulating blood cells due to anemia, or neutropenia due to neutrophilia or eosinophilia. Signs of a high circulating blood level of a hematological neoplasm can include a rapid increase in the level of the blood cell's constituent plasma protein (or anemia), or decreased blood platelet number. Other bleeding symptoms such as an easy bruising or nosebleed may appear due to platelet or coagulation disorders, or decreased number of red blood cells in circulation with anemia as a result." - Anonymous Online Contributor
"The majority of hematologic malignancies are caused by chemical exposures, viruses, chromosomal abnormalities, and autoimmune diseases. Many neoplasms are associated with aging and exposure to environmental agents. The carcinogen hypothesis proposes that environmental exposures are important factors in the causation of carcinoma." - Anonymous Online Contributor
"Treatment of hematologic neoplasms is largely based on the stage of the disease and the severity of the symptoms experienced. The treatment can be a combination of both chemotherapy and local therapies, particularly in localized cases of disease. Chemotherapy is usually given for multiple myeloma or leukemia. Local therapies may include radiotherapy or treatment with interferon-alpha for multiple myeloma." - Anonymous Online Contributor
"Causes of hematologic neoplasms include cancer, which is the most common type of hematologic neoplasm (38%), and inherited disorders, mainly genetic disorders (13%). [Power (http://www.withpower.com/hematologic-diseases/hereditary-disorders-hematological-diseases) can link to specific hereditary diseases and their associated mutations(http://geneva.gsa.gov/HGNC/mutations/qportal/).] Hematologic disorders are characterized by a high risk of new neoplasms and their associated symptoms. [Power(http://www.withpower." - Anonymous Online Contributor
"Bortezomib therapy in advanced hematological malignancies is associated with rapid, durable responses including complete responses and a reduced risk of serious adverse events. Bortezomib should be further studied in different clinical settings." - Anonymous Online Contributor
"In the past 2 decades, important new insights have been made in the treatment of hematopoietic neoplasms. In addition to conventional chemotherapy and the newly emerging therapeutic agents, targeted therapy including immunoassays and stem cell transplantation have become more valuable in treating hematological malignancies." - Anonymous Online Contributor
"Patients with acute leukemia tend to have large tumor masses, but the clinical stage, disease grade, and subtype seem to not be significantly associated with the spread rate, time spent in hospital, or clinical death rate. The study results reveal no correlation between survival outcomes or disease dissemination and the presence of B cell or T cell neoplasms." - Anonymous Online Contributor
"Current developments aim at a better understanding of the mechanism responsible for tumor cell growth inhibition, aiming at the blockade of the proteasome-dependent cytotoxic activity of bortezomib itself and at the development of bortezomib analogues which display greater selectivity in the inactivation of the proteasome." - Anonymous Online Contributor
"In addition to the severity of the symptoms, clinical symptoms and hematologic values are not always related to the seriousness of the disease and only the type of pathogen affects the time of onset of disease. If the diagnosis is missed on the first admission, some of the cases can be saved by early diagnostic measures." - Anonymous Online Contributor